Loading cancer entity…
Loading cancer entity…
Clinical trials
3,386 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00002850 | Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy | completed | Phase 3 | 212 | Gary MorrowOTHER | 3 | Nov 11, 2015 | clinicaltrials |
| NCT00103506 | Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | completed | Phase 3 | 646 | Janssen Research & Development, LLCINDUSTRY | 17 | Oct 19, 2015 |
| NCT01621672 | UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma | completed | Phase 3 | 42 | University of ArkansasOTHER | 1 | Oct 19, 2015 | clinicaltrials |
| NCT00276536 | Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma(IFNa) | completed | Phase 1 | 35 | The Cleveland ClinicOTHER | 1 | Oct 14, 2015 | clinicaltrials |
| NCT01485835 | A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Emory UniversityOTHER | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00111748 | UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients | completed | Phase 3 | 180 | University of ArkansasOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01521533 | NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma | completed | Phase 2 | 28 | TME Pharma AGINDUSTRY | 4 | Oct 6, 2015 | clinicaltrials |
| NCT01084837 | Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure(RENVEL) | completed | Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT00057564 | A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma | completed | Phase 3 | 470 | Celgene CorporationINDUSTRY | 16 | Sep 11, 2015 | clinicaltrials |
| NCT00915408 | A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma(CRD) | completed | Phase 1 / Phase 2 | 32 | King's College Hospital NHS TrustOTHER | 1 | Sep 2, 2015 | clinicaltrials |
| NCT00060632 | Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) | completed | Phase 1 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT00060645 | Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) | completed | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 27, 2015 | clinicaltrials |
| NCT00217438 | Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma | completed | Phase 3 | 130 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 21, 2015 | clinicaltrials |
| NCT01085214 | AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00572338 | Therapeutic Research in Multiple Myeloma | completed | — | 6,388 | University of ArkansasOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01658319 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT02221479 | Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma | completed | Phase 2 | 14 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 4, 2015 | clinicaltrials |
| NCT01508416 | Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma(METRO) | completed | — | 71 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jul 28, 2015 | clinicaltrials |
| NCT01066624 | Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation | completed | N/A | 117 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00131261 | Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Jul 8, 2015 | clinicaltrials |
| NCT02474563 | Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma | completed | — | 171 | Janssen Korea, Ltd., KoreaINDUSTRY | 1 | Jun 30, 2015 | clinicaltrials |
| NCT00398411 | Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells(MoxiProph) | completed | Phase 3 | 66 | University of CologneOTHER | 1 | Jun 29, 2015 | clinicaltrials |
| NCT00689507 | A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib | completed | Phase 1 | 48 | Applied Molecular EvolutionINDUSTRY | 1 | Jun 29, 2015 | clinicaltrials |
| NCT00083382 | Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide | completed | Phase 2 | 83 | University of ArkansasOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT01531998 | Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT02117115 | Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation(GVHD) | completed | Early Phase 1 | 21 | Washington University School of MedicineOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00201695 | Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma | completed | Phase 2 | 12 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT02467010 | Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance(REMM) | completed | Phase 2 | 73 | University Medical Center GroningenOTHER | 1 | Jun 9, 2015 | clinicaltrials |
| NCT01344876 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | completed | Phase 1 | 20 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00111813 | Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | completed | Phase 1 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 21, 2015 | clinicaltrials |
| NCT00998049 | Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | May 14, 2015 | clinicaltrials |
| NCT00778752 | Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | completed | Phase 1 / Phase 2 | 24 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT01160484 | Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 40 | OncotherapeuticsINDUSTRY | 1 | May 4, 2015 | clinicaltrials |
| NCT00871663 | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) | completed | Phase 1 | 123 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 20, 2015 | clinicaltrials |
| NCT00440479 | ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. | completed | — | 11 | Janssen-Cilag B.V.INDUSTRY | 1 | Apr 16, 2015 | clinicaltrials |
| NCT01533194 | Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00577096 | Effects of Exercise in Combination With Epoetin Alfa | completed | N/A | 120 | University of ArkansasOTHER | 1 | Apr 6, 2015 | clinicaltrials |
| NCT00919139 | S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. | completed | — | 190 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 3, 2015 | clinicaltrials |
| NCT00434161 | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma | completed | Phase 3 | 281 | Swedish Orphan BiovitrumINDUSTRY | 1 | Mar 30, 2015 | clinicaltrials |
| NCT00064038 | S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | completed | Phase 3 | 198 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 25, 2015 | clinicaltrials |
| NCT00741780 | Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662). | completed | — | 164 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Mar 24, 2015 | clinicaltrials |
| NCT00066638 | FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2015 | clinicaltrials |
| NCT00972712 | Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | Emory UniversityOTHER | 2 | Mar 10, 2015 | clinicaltrials |
| NCT00002548 | SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma | completed | Phase 3 | 899 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00002849 | S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 93 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00416273 | A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma | completed | Phase 3 | 217 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00416208 | Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma | completed | Phase 3 | 154 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01622582 | Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma | completed | — | 796 | University of ArkansasOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT02035189 | Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients | completed | — | 100 | University of ArkansasOTHER | 1 | Mar 3, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Nov 11, 2015source: clinicaltrials